ATE520708T1 - Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung - Google Patents

Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung

Info

Publication number
ATE520708T1
ATE520708T1 AT04749556T AT04749556T ATE520708T1 AT E520708 T1 ATE520708 T1 AT E520708T1 AT 04749556 T AT04749556 T AT 04749556T AT 04749556 T AT04749556 T AT 04749556T AT E520708 T1 ATE520708 T1 AT E520708T1
Authority
AT
Austria
Prior art keywords
nucleic acid
acid molecules
hiv
epitopes
encode
Prior art date
Application number
AT04749556T
Other languages
English (en)
Inventor
Renu Lal
Sherry Owen
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE520708T1 publication Critical patent/ATE520708T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04749556T 2003-03-28 2004-03-26 Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung ATE520708T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45888003P 2003-03-28 2003-03-28
PCT/US2004/009767 WO2004085466A2 (en) 2003-03-28 2004-03-26 Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use

Publications (1)

Publication Number Publication Date
ATE520708T1 true ATE520708T1 (de) 2011-09-15

Family

ID=33098288

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04749556T ATE520708T1 (de) 2003-03-28 2004-03-26 Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung

Country Status (6)

Country Link
US (1) US7425611B2 (de)
EP (1) EP1608675B1 (de)
AT (1) ATE520708T1 (de)
AU (1) AU2004223855B8 (de)
CA (1) CA2519025A1 (de)
WO (1) WO2004085466A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
US7951377B2 (en) 2005-08-23 2011-05-31 Los Alamos National Security, Llc Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
US8119140B2 (en) 2005-08-23 2012-02-21 Los Alamos Security, LLC Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins
US20110110974A1 (en) * 2007-10-29 2011-05-12 Erik Depla Methods and kits for inducing a ctl response using a prime boost regimen
US20130195904A1 (en) * 2010-01-04 2013-08-01 National University Of Singapore Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications
US10898555B2 (en) * 2013-07-02 2021-01-26 Japanese Foundation For Cancer Research Cellular immunity inducing vaccine
US10238741B2 (en) 2014-10-10 2019-03-26 The Trustees Of Columbia University In The City Of New York Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof
WO2016057986A1 (en) * 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
JP2022521410A (ja) * 2019-02-21 2022-04-07 センティヴァックス， インコーポレイテッド 最適化されたワクチン組成物およびその製造方法
WO2020186064A1 (en) 2019-03-12 2020-09-17 The General Hospital Corporation Highly networked immunogen composition
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
WO2021185851A1 (en) * 2020-03-17 2021-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccine compositions for hiv prevention and treatment
CA3202466A1 (en) 2021-01-14 2022-07-21 Jiani LI Hiv vaccines and methods of using

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633234A (en) * 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US6319503B1 (en) * 1998-02-19 2001-11-20 Proteinix Company Heat shock fusion-based vaccine system
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
US20020182222A1 (en) * 1998-07-10 2002-12-05 Groot Anne De HIV vaccine candidate peptides
US6656471B1 (en) 1998-11-17 2003-12-02 Board Of Regents, The University Of Texas System HIV-specific T-cell induction
WO2001012216A1 (en) 1999-08-13 2001-02-22 Proteinix Company Heat shock fusion-based vaccine system
EP2100620A1 (de) 1999-09-16 2009-09-16 Eisai Corporation of North America Polyepitop-Polypeptide kodierende Nukleinsäuren
EP1225907A4 (de) 1999-10-05 2005-06-22 Epimmune Inc Induktion zellulärer immunantworten gegen humanes immundefiziens virus-1 (hiv-1) mittels peptid- und nukleinsäureverbindungen
DK1240186T3 (da) * 1999-12-23 2010-05-31 Medical Res Council Forbedringer i eller relateret til immunrespons mod HIV
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP1130089A1 (de) * 2000-02-17 2001-09-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Membranvirus Ziel- und Fusion-subvirale Partikel enthaltende Zusammensetzung und diese enthaltende Impstoff
DE10010292A1 (de) 2000-03-02 2001-09-06 Zahnradfabrik Friedrichshafen Fahrzeugachse
US20040241140A1 (en) 2000-11-01 2004-12-02 Pavlakis George N. Expression vectors able to elicit improved immune response and methods of using same
US20030003440A1 (en) * 2001-03-14 2003-01-02 Lucia Lopalco Novel CCR5 epitope and antibodies against it
ES2404689T3 (es) 2001-04-05 2013-05-28 The Johns Hopkins University Vacunas quiméricas que comprenden el dominio lumenal de LAMP-1 o LAMP-2
CA2357906A1 (en) 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
CN1325512C (zh) 2002-05-16 2007-07-11 巴法里安诺迪克有限公司 Hiv调节/辅助蛋白的融合蛋白

Also Published As

Publication number Publication date
EP1608675B1 (de) 2011-08-17
CA2519025A1 (en) 2004-10-07
WO2004085466A3 (en) 2005-03-24
AU2004223855B8 (en) 2011-03-17
AU2004223855A1 (en) 2004-10-07
US20060216305A1 (en) 2006-09-28
WO2004085466A2 (en) 2004-10-07
US7425611B2 (en) 2008-09-16
AU2004223855B2 (en) 2010-06-17
EP1608675A2 (de) 2005-12-28
WO2004085466A8 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
PH12020551907A1 (en) Antagonizing cd73 antibody
NO20064059L (no) Albumin fusjonsproteiner
EA202091710A1 (ru) Антитела против cd73 и способы их применения
ATE533782T1 (de) Impfstoffe und immuntherapeutika mit codon- optimiertem il-15 und verwendungsverfahren dafür
CY1116582T1 (el) Ανθρωπινα αντισωματα που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (leg-3), και χρησεις εξ' αυτων
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
BRPI1008692B8 (pt) anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
EA201590138A1 (ru) Оптимизация антител, которые связывают ген активации лимфоцитов 3 (lag-3), и их применение
MX2009002816A (es) Proteinas de fusion de albumina.
TNSN08064A1 (en) Albumin fusion proteins
EA201491171A1 (ru) Вещества, содержащие улучшенные генетические конструкции il-12, вакцины, иммунотерапевтические составы и способы их применения
MX383614B (es) Proteinas de union triespecificas y metodos de uso.
BRPI0507489A (pt) anticorpos humanos de anti-cd38 e para os seus usos
EA200702093A1 (ru) Антитела-миметики glp-1 человека, композиции, способы и их применение
NO20091387L (no) Antistoffer mot benmorfogene proteiner og reseptorer derav, fremgangsmater for deres anvendelse
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
AR072680A1 (es) Axmi-115 axmi-113 axmi-005 axmi-163 y axmi-184 proteinas insecticidas y metodos de uso de las mismas
UA101301C2 (ru) ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ
WO2004085466A3 (en) Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
ATE522541T1 (de) Bakterielle adhäsine konformere
Leblanc et al. VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever
ATE473236T1 (de) Antigene von piscirickettsia salmonis und deren verwendung
EA202191658A1 (ru) Антитела против фактора c2b комплемента человека и способы применения
WO2018102774A8 (en) Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein a

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties